{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:22:17Z","timestamp":1780057337616,"version":"3.54.0"},"reference-count":49,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Health and Human Services","award":["HHSO1002019000022C"],"award-info":[{"award-number":["HHSO1002019000022C"]}]},{"name":"Office of the Assistant Secretary for Preparedness and Response","award":["HHSO1002019000022C"],"award-info":[{"award-number":["HHSO1002019000022C"]}]},{"name":"Biomedical Advanced Research and Development Authority","award":["HHSO1002019000022C"],"award-info":[{"award-number":["HHSO1002019000022C"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Filoviruses, like the Marburg (MARV) and Ebola (EBOV) viruses, have caused outbreaks associated with significant hemorrhagic morbidity and high fatality rates. Vaccines offer one of the best countermeasures for fatal infection, but to date only the EBOV vaccine has received FDA licensure. Given the limited cross protection between the EBOV vaccine and Marburg hemorrhagic fever (MHF), we analyzed the protective efficacy of a similar vaccine, rVSV-MARV, in the lethal cynomolgus macaque model. NHPs vaccinated with a single dose (as little as 1.6 \u00d7 107 pfu) of rVSV-MARV seroconverted to MARV G-protein prior to challenge on day 42. Vaccinemia was measured in all vaccinated primates, self-resolved by day 14 post vaccination. Importantly, all vaccinated NHPs survived lethal MARV challenge, and showed no significant alterations in key markers of morbid disease, including clinical signs, and certain hematological and clinical chemistry parameters. Further, apart from one primate (from which tissues were not collected and no causal link was established), no pathology associated with Marburg disease was observed in vaccinated animals. Taken together, rVSV-MARV is a safe and efficacious vaccine against MHF in cynomolgus macaques.<\/jats:p>","DOI":"10.3390\/v16081181","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T08:47:17Z","timestamp":1721810837000},"page":"1181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7926-0950","authenticated-orcid":false,"given":"Vidyleison N.","family":"Camargos","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannan L.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Microbiology and Immunology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7034-2602","authenticated-orcid":false,"given":"Terry L.","family":"Juelich","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer K.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-3289","authenticated-orcid":false,"given":"Nikos","family":"Vasilakis","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Center for Vector-Borne and Zoonotic Diseases, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-8960","authenticated-orcid":false,"given":"Alexander N.","family":"Freiberg","sequence":"additional","affiliation":[{"name":"Departments of Pathology, Microbiology and Immunology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-3400","authenticated-orcid":false,"given":"Rick","family":"Nichols","sequence":"additional","affiliation":[{"name":"Public Health Vaccines, LLC, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3716-5688","authenticated-orcid":false,"given":"Joan","family":"Fusco","sequence":"additional","affiliation":[{"name":"Public Health Vaccines, LLC, Cambridge, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jcv.2006.12.023","article-title":"Viral load among patients infected with Marburgvirus in Angola","volume":"39","author":"Weidmann","year":"2007","journal-title":"J. Clin. Virol."},{"key":"ref_2","unstructured":"CDC Health Alert Network (2024, April 11). Marburg Virus Disease Outbreaks in Equatorial Guinea and Tanzania, Available online: https:\/\/emergency.cdc.gov\/han\/2023\/han00489.asp."},{"key":"ref_3","first-page":"307","article-title":"Marburg virus disease outbreaks, mathematical models, and disease parameters: A systematic review","volume":"24","author":"McCain","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/trstmh\/trv024","article-title":"Mapping the zoonotic niche of Marburg virus disease in Africa","volume":"109","author":"Pigott","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(23)00169-1","article-title":"Developing a vaccine against Marburg virus disease","volume":"401","author":"Manno","year":"2023","journal-title":"Lancet"},{"key":"ref_6","unstructured":"World Health Organization (2024, February 25). Marburg Virus Disease. Available online: https:\/\/www.who.int\/News-Room\/Fact-Sheets\/Detail\/Marburg-Virus-Disease."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_9","unstructured":"FDA (2024, February 13). First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wolfe, D.N., Sabourin, C.L., Merchlinsky, M.J., Florence, W.C., Wolfraim, L.A., Taylor, K.L., and Ward, L.A. (2021). Selection of Filovirus Isolates for Vaccine Development Programs. Vaccines, 9.","DOI":"10.3390\/vaccines9091045"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Taylor, K.L., Lanning, L., Wolfraim, L., Shrivastava Gales, S., Sico, C., Dowling, W.E., Ward, L.A., Florence, W.C., Nuzum, E., and Bryant, P.R. (2022). A U.S. Government-Coordinated Effort to Leverage Non-Human Primate Data to Facilitate Ebolavirus Vaccine Development. Vaccines, 10.","DOI":"10.3390\/vaccines10081201"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Comer, J.E., Brasel, T., Massey, S., Beasley, D.W., Cirimotich, C.M., Sanford, D.C., Chou, Y.L., Niemuth, N.A., Novak, J., and Sabourin, C.L. (2022). Natural History of Marburg Virus Infection to Support Medical Countermeasure Development. Viruses, 14.","DOI":"10.3390\/v14102291"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zumbrun, E.E., Garvey, C.B., Wells, J.B., Lynn, G.C., Van Tongeren, S., Steffens, J.T., Wetzel, K.S., Gomba, L.M., O\u2019Brien, K.A., and Rossi, F.D. (2023). Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing. Viruses, 15.","DOI":"10.3390\/v15122335"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Alfson, K.J., Goez-Gazi, Y., Gazi, M., Chou, Y.L., Niemuth, N.A., Mattix, M.E., Staples, H.M., Klaffke, B., Rodriguez, G.F., and Bartley, C. (2022). Development of a Well-Characterized Cynomolgus Macaque Model of Marburg Virus Disease for Support of Vaccine and Therapy Development. Vaccines, 10.","DOI":"10.1101\/2022.05.04.490569"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"250ra116","DOI":"10.1126\/scitranslmed.3009706","article-title":"Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA","volume":"6","author":"Thi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mire, C.E., Geisbert, J.B., Agans, K.N., Satterfield, B.A., Versteeg, K.M., Fritz, E.A., Feldmann, H., Hensley, L.E., and Geisbert, T.W. (2014). Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094355"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Marzi, A., Menicucci, A.R., Engelmann, F., Callison, J., Horne, E.J., Feldmann, F., Jankeel, A., Feldmann, H., and Messaoudi, I. (2018). Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.03071"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/JVI.01190-17","article-title":"Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge","volume":"92","author":"Matassov","year":"2018","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cooper, C.L., Morrow, G., Yuan, M., Coleman, J.W., Hou, F., Reiserova, L., Li, S.L., Wagner, D., Carpov, A., and Wallace-Selman, O. (2022). Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials. Vaccines, 10.","DOI":"10.3390\/vaccines10101582"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3201\/eid1607.100159","article-title":"Postexposure treatment of Marburg virus infection","volume":"16","author":"Geisbert","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(06)68546-2","article-title":"Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment","volume":"367","author":"Geisbert","year":"2006","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI131958","article-title":"Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death","volume":"130","author":"Cross","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1038\/s41598-020-59976-3","article-title":"Immune correlates of postexposure vaccine protection against Marburg virus","volume":"10","author":"Woolsey","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhu, W., Liu, G., Cao, W., He, S., Leung, A., Stroher, U., Fairchild, M.J., Nichols, R., Crowell, J., and Fusco, J. (2022). A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease. Vaccines, 10.","DOI":"10.3390\/vaccines10071004"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Johnston, S.C., Lin, K.L., Twenhafel, N.A., Raymond, J.L., Shamblin, J.D., Wollen, S.E., Wlazlowski, C.B., Wilkinson, E.R., Botto, M.A., and Goff, A.J. (2015). Dose Response of MARV\/Angola Infection in Cynomolgus Macaques following IM or Aerosol Exposure. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138843"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1093\/infdis\/jiad157","article-title":"A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus","volume":"228","author":"Woolsey","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-021-22132-0","article-title":"Combination therapy protects macaques against advanced Marburg virus disease","volume":"12","author":"Cross","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rudge, T.L., Machesky, N.J., Sankovich, K.A., Lemmon, E.E., Badorrek, C.S., Overman, R., Niemuth, N.A., and Anderson, M.S. (2022). Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay. Vaccines, 10.","DOI":"10.3390\/vaccines10081211"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.celrep.2017.03.049","article-title":"Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus","volume":"19","author":"Howell","year":"2017","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tell, J.G., Coller, B.G., Dubey, S.A., Jenal, U., Lapps, W., Wang, L., and Wolf, J. (2020). Environmental Risk Assessment for rVSVDeltaG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease. Vaccines, 8.","DOI":"10.3390\/vaccines8040779"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4269\/ajtmh.19-0076","article-title":"Effect of Gamma Irradiation on the Antibody Response Measured in Human Serum from Subjects Vaccinated with Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine","volume":"101","author":"Antonello","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4269\/ajtmh.20-1055","article-title":"Effects of Gamma Irradiation of Human Serum Samples from rVSVDeltaG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays","volume":"104","author":"Antonello","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_35","first-page":"241","article-title":"A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the \u2018Animal Rule\u2019","volume":"65","author":"Glaze","year":"2015","journal-title":"Comp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Lehrer, A.T., Chuang, E., Namekar, M., Williams, C.A., Wong, T.A.S., Lieberman, M.M., Granados, A., Misamore, J., Yalley-Ogunro, J., and Andersen, H. (2021). Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.703986"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e88864","DOI":"10.1172\/jci.insight.88864","article-title":"Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea","volume":"2","author":"Vernet","year":"2017","journal-title":"JCI Insight"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12985-019-1272-z","article-title":"Marburg virus pathogenesis\u2014Differences and similarities in humans and animal models","volume":"16","author":"Shifflett","year":"2019","journal-title":"Virol. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","article-title":"Clinical illness and outcomes in patients with Ebola in Sierra Leone","volume":"371","author":"Schieffelin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijid.2020.07.042","article-title":"Marburg virus disease: A summary for clinicians","volume":"99","author":"Kortepeter","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rozo-Lopez, P., Drolet, B.S., and Londono-Renteria, B. (2018). Vesicular Stomatitis Virus Transmission: A Comparison of Incriminated Vectors. Insects, 9.","DOI":"10.3390\/insects9040190"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2217\/imt.13.124","article-title":"An update on the use of antibodies against the filoviruses","volume":"5","author":"Saphire","year":"2013","journal-title":"Immunotherapy"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Geisbert, T.W., Daddario-Dicaprio, K.M., Lewis, M.G., Geisbert, J.B., Grolla, A., Leung, A., Paragas, J., Matthias, L., Smith, M.A., and Jones, S.M. (2008). Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000225"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell, K.L., Feldmann, F., Kaza, B., Clancy, C.S., Hanley, P.W., Fletcher, P., and Marzi, A. (2023). Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine. EBioMedicine, 89.","DOI":"10.1016\/j.ebiom.2023.104463"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Marzi, A., Jankeel, A., Menicucci, A.R., Callison, J., O\u2019Donnell, K.L., Feldmann, F., Pinski, A.N., Hanley, P.W., and Messaoudi, I. (2021). Single Dose of a VSV-Based Vaccine Rapidly Protects Macaques From Marburg Virus Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.774026"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Woolsey, C., Cross, R.W., Agans, K.N., Borisevich, V., Deer, D.J., Geisbert, J.B., Gerardi, C., Latham, T.E., Fenton, K.A., and Egan, M.A. (2022). A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl. Trop. Dis., 16.","DOI":"10.1101\/2022.01.22.477345"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/fvl.11.79","article-title":"Clinical aspects of Marburg hemorrhagic fever","volume":"6","author":"Mehedi","year":"2011","journal-title":"Future Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1093\/infdis\/jiv182","article-title":"Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model","volume":"212","author":"Cross","year":"2015","journal-title":"J. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:22:05Z","timestamp":1760109725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/8\/1181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["v16081181"],"URL":"https:\/\/doi.org\/10.3390\/v16081181","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]}}}